|
Daily Medical Update
Polycythemia & Thrombocytosis Evaluation
Saturday, March 28, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Clinical laboratory (2024) - Retrospective study
Key Findings
- In polycythemia evaluations, JAK2 positivity was 16.7% (22/136), indicating that many screened patients did not have PV despite elevated counts.
- PV-confirmed cases showed leukocytosis and thrombocytosis vs secondary altitude-related erythrocytosis patterns, improving diagnostic discrimination.
📋 Practice Implication: Use a triage bundle (CBC pattern + EPO + JAK2) before broad PV workup in high-altitude or hypoxia-exposed patients to reduce low-yield testing.
|
Annals of hematology (2026) - Retrospective single-center study
Key Findings
- Compared with ET, PV had lower transferrin saturation (12.9% vs 21.64%) and lower EPO (2.23 vs 6.11 mIU/mL), with p < 0.001 for key contrasts.
- JAK2 VAF was higher in PV (48% vs 21%, p = 0.003), and integrating VAF with iron-functional markers improved separation of borderline PV vs ET presentations.
📋 Practice Implication: When PV-versus-ET classification is equivocal, add transferrin saturation and JAK2 allele burden to routine diagnostic panels rather than relying on ferritin or hemoglobin alone.
|
European journal of haematology (2023) - Population-based retrospective cohort
Key Findings
- Among 3931 thromboembolism patients, 1195 (30.4%) had elevated Hb/Hct/platelets and 411 met criteria for deeper MPN evaluation, showing a substantial missed-disease pool.
- Unexplained thrombocytosis and secondary erythrocytosis were linked to increased recurrent event risk and reduced survival vs patients without these count abnormalities.
📋 Practice Implication: After any thromboembolic event with unexplained erythrocytosis or thrombocytosis, initiate expedited MPN-focused testing and hematology follow-up to prevent recurrent events.
|
|
Current evidence supports a tiered evaluation pathway for polycythemia and thrombocytosis that moves beyond isolated CBC thresholds to integrated clonal-risk assessment. Across contemporary cohorts, combining CBC pattern recognition with JAK2 testing, iron functional markers, and thrombotic-context review improves identification of patients likely to have clinically meaningful myeloproliferative disease. For frontline practice, the highest-yield diagnostic gains come from targeted molecular testing in high-risk phenotypes and from early workup of unexplained cytoses after thromboembolic events.
|
|